Patent 9040050 was granted and assigned to Genmab A/S on May, 2015 by the United States Patent and Trademark Office.
The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non-corticosteroid chemotherapeutic agent.